 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of renal [0m
[34mfailure?[0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ENALAPRIL MALEATE increase or decrease the risk of renal [0m
[32mfailure?[0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ENALAPRIL MALEATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ENALAPRIL MALEATE: general_precautions: General Aortic Stenosis/Hypertrophic Cardiomyopathy As with all vasodilators, enalapril should be given with caution to patients with obstruction in [0m
[31mthe outflow tract of the left ventricle. Impaired Renal Function As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible [0m
[31mindividuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors,[0m
[31mincluding enalapril maleate, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. In clinical studies in [0m
[31mhypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in [0m[1;31m20[0m[31m percent of patients. ENALAPRIL MALEATE: [0m
[31mgeneral_precautions: These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few [0m
[31mweeks of therapy. Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and [0m
[31mtransient, especially when enalapril maleate has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or [0m
[31mdiscontinuation of the diuretic and/or enalapril maleate may be required. Evaluation of patients with hypertension or heart failure should always include assessment of renal function [0m[1;31m([0m[31m see DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m. Hyperkalemia Elevated serum potassium [0m[1;31m([0m[31mgreater than [0m[1;31m5.7[0m[31m mEq/L[0m[1;31m)[0m[31m was observed in approximately [0m[1;31m1[0m[31m percent of hypertensive patients in clinical trials. In most cases these were isolated [0m
[31mvalues which resolved despite continued therapy. ENALAPRIL MALEATE: general_precautions: Hyperkalemia was a cause of discontinuation of therapy in [0m[1;31m0.28[0m[31m percent of hypertensive patients. In clinical [0m
[31mtrials in heart failure, hyperkalemia was observed in [0m[1;31m3.8[0m[31m percent of patients but was not a cause for discontinuation. Risk factors for the development of hyperkalemia include renal insufficiency, [0m
[31mdiabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with [0m
[31menalapril maleate [0m[1;31m([0m[31msee Drug Interactions [0m[1;31m)[0m[31m. Cough Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE [0m
[31minhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough. ENALAPRIL MALEATE: general_precautions: [0m
[31mSurgery/Anesthesia In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release.[0m
[31mIf hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: clinical_pharmacology: Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of [0m
[31menalapril maleate in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of [0m[1;31m14[0m[31m C-enalapril maleate. Radioactivity was found to [0m
[31mcross the placenta following administration of labeled drug to pregnant hamsters. Pharmacodynamics and Clinical Effects Hypertension Administration of enalapril maleate to patients with hypertension [0m
[31mof severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore [0m
[31minfrequent, although it might be anticipated in volume-depleted patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: clinical_pharmacology: In most patients studied, after oral administration of [0m
[31ma single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours. At recommended doses, antihypertensive effects [0m
[31mhave been maintained for at least [0m[1;31m24[0m[31m hours. In some patients the effects may diminish toward the end of the dosing interval [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , Hypertension [0m[1;31m)[0m[31m. In some patients [0m
[31machievement of optimal blood pressure reduction may require several weeks of therapy. The antihypertensive effects of enalapril maleate have continued during long-term therapy. Abrupt withdrawal of [0m
[31menalapril maleate has not been associated with a rapid increase in blood pressure. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a [0m
[31mreduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. ENALAPRIL MALEATE: clinical_pharmacology: Following administration of enalapril [0m
[31mmaleate, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension. When given together [0m
[31mwith thiazide-type diuretics, the blood pressure lowering effects of enalapril maleate are approximately additive. In a clinical pharmacology study, indomethacin or sulindac was administered to [0m
[31mhypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. Heart [0m
[31mFailure In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure and [0m
[31mheart size, and increased cardiac output and exercise tolerance. ENALAPRIL MALEATE: clinical_pharmacology: Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or [0m
[31mincreased. There was a beneficial effect on severity of heart failure as measured by the New York Heart Association [0m[1;31m([0m[31mNYHA[0m[1;31m)[0m[31m classification and on symptoms of dyspnea and fatigue. Hemodynamic effects [0m
[31mwere observed after the first dose and appeared to be maintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart [0m
[31mfailure were observed in placebo-controlled studies lasting from eight weeks to over one year. Heart Failure, Mortality Trials In a multicenter, placebo-controlled clinical trial, [0m[1;31m2[0m[31m,[0m[1;31m569[0m[31m patients with [0m
[31mall degrees of symptomatic heart failure and ejection fraction ≤[0m[1;31m35[0m[31m percent were randomized to placebo or enalapril and followed for up to [0m[1;31m55[0m[31m months [0m[1;31m([0m[31mSOLVD-Treatment[0m[1;31m)[0m[31m. Use of enalapril was associated [0m
[31mwith an [0m[1;31m11[0m[31m percent reduction in all-cause mortality and a [0m[1;31m30[0m[31m percent reduction in hospitalization for heart failure. ENALAPRIL MALEATE: clinical_pharmacology: Diseases that excluded patients from [0m
[31menrollment in the study included severe stable angina [0m[1;31m([0m[31m>[0m[1;31m2[0m[31m attacks/day[0m[1;31m)[0m[31m, hemodynamically significant valvular or outflow tract obstruction, renal failure [0m[1;31m([0m[31mcreatinine >[0m[1;31m2.5[0m[31m mg/dL[0m[1;31m)[0m[31m, cerebrovascular [0m
[31mdisease [0m[1;31m([0m[31me.g., significant carotid artery disease[0m[1;31m)[0m[31m, advanced pulmonary disease, malignancies, active myocarditis and constrictive pericarditis. The mortality benefit associated with enalapril does not[0m
[31mappear to depend upon digitalis being present. A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left [0m
[31mventricular ejection fraction ≤[0m[1;31m35[0m[31m percent and no history of symptomatic heart failure, were randomized to placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m117[0m[1;31m)[0m[31m or enalapril [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m111[0m[1;31m)[0m[31m and followed for up to [0m[1;31m5[0m[31m years. ENALAPRIL MALEATE: [0m
[31mclinical_pharmacology: The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in [0m[1;31m80[0m[31m percent of patients, current[0m
[31mangina pectoris in [0m[1;31m34[0m[31m percent, and a history of hypertension in [0m[1;31m37[0m[31m percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had [0m[1;31m32[0m[31m percent[0m
[31mfewer first hospitalizations for heart failure, and [0m[1;31m32[0m[31m percent fewer total heart failure hospitalizations. Compared to placebo, [0m[1;31m32[0m[31m percent fewer patients receiving enalapril developed symptoms of [0m
[31movert heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group [0m[1;31m([0m[31mfor [0m
[31menalapril vs. placebo, respectively, [0m[1;31m1166[0m[31m vs. [0m[1;31m1201[0m[31m first hospitalizations, [0m[1;31m2649[0m[31m vs. [0m[1;31m2840[0m[31m total hospitalizations[0m[1;31m)[0m[31m, although the study was not powered to look for such an effect.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Enalapril maleate tablets, USP are indicated for the treatment of hypertension. Enalapril maleate tablets, USP are[0m
[31meffective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately [0m
[31madditive. Heart Failure Enalapril maleate tablets, USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients [0m
[31menalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of [0m
[31msurvival trials[0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction [0m[1;31m([0m[31mejection fraction [0m
[31m≤[0m[1;31m35[0m[31m percent[0m[1;31m)[0m[31m, enalapril maleate tablets, USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart[0m
[31mFailure, Mortality Trials for details and limitations of survival trials[0m[1;31m)[0m[31m. In using enalapril maleate, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, [0m
[31mcaptopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not [0m
[31mhave a similar risk [0m[1;31m([0m[31msee WARNINGS , Neutropenia/Agranulocytosis [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: In considering use of enalapril maleate, it should be noted that in controlled clinical [0m
[31mtrials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been [0m
[31mreported to have a higher incidence of angioedema compared to non-blacks [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: warnings: Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain [0m[1;31m([0m[31mwith or [0m
[31mwithout nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or[0m
[31multrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with [0m
[31mabdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [0m[1;31m([0m[31msee INDICATIONS AND USAGE and [0m
[31mCONTRAINDICATIONS [0m[1;31m)[0m[31m. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening [0m
[31manaphylactoid reactions. ENALAPRIL MALEATE: warnings: In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent [0m
[31mrechallenge. Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. [0m
[31mAnaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. Hypotension Excessive hypotension is rare in uncomplicated [0m
[31mhypertensive patients treated with enalapril maleate alone. Patients with heart failure given enalapril maleate commonly have some reduction in blood pressure, especially with the first dose, but [0m
[31mdiscontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy [0m[1;31m([0m[31msee DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or [0m
[31mdeath, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, [0m
[31mor severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic [0m[1;31m([0m[31mexcept in patients with heart failure[0m[1;31m)[0m[31m, reduce the diuretic dose or increase salt intake [0m
[31mcautiously before initiating therapy with enalapril maleate in patients at risk for excessive hypotension who are able to tolerate such adjustments [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions and ADVERSE [0m
[31mREACTIONS [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for[0m
[31mthe first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom [0m
[31man excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident. If excessive hypotension occurs, the patient should be placed in the supine position and, if [0m
[31mnecessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of enalapril maleate, which usually can be given without [0m
[31mdifficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of enalapril maleate or concomitant diuretic may be necessary. ENALAPRIL [0m
[31mMALEATE: warnings: Neutropenia/Agranulocytosis Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated [0m
[31mpatients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that[0m
[31menalapril does not cause agranulocytosis at similar rates. Marketing experience has revealed cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. [0m
[31mPeriodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered. Hepatic Failure Rarely, ACE inhibitors have been associated with a [0m
[31msyndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and [0m[1;31m([0m[31msometimes[0m[1;31m)[0m[31m death. The mechanism of this syndrome is not understood.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: Cardiovascular Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients [0m[1;31m([0m[31msee [0m
[31mWARNINGS, Hypotension [0m[1;31m)[0m[31m; pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation, Raynaud's phenomenon. [0m
[31mDigestive Ileus, pancreatitis, hepatic failure, hepatitis [0m[1;31m([0m[31mhepatocellular [0m[31m or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, melena, anorexia, dyspepsia, constipation, glossitis, stomatitis, [0m
[31mdry mouth. Hematologic Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Musculoskeletal Muscle cramps. ENALAPRIL MALEATE: adverse_reactions: Nervous/Psychiatric Depression, [0m
[31mconfusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy [0m[1;31m([0m[31me.g., paresthesia, dysesthesia[0m[1;31m)[0m[31m, dream abnormality. Respiratory Bronchospasm, rhinorrhea, sore throat and hoarseness, [0m
[31masthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis. Skin Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, herpes zoster, [0m
[31merythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity. Special Senses Blurred vision, taste alteration, anosmia, tinnitus, conjunctivitis, dry eyes, tearing. [0m
[31mENALAPRIL MALEATE: adverse_reactions: Urogenital Renal failure, oliguria, renal dysfunction [0m[1;31m([0m[31msee PRECAUTIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m, flank pain, gynecomastia, impotence. Miscellaneous A [0m
[31msymptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia/myositis, fever, serositis, [0m
[31mvasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Angioedema Angioedema has been reported in patients receiving enalapril maleate, with an incidence[0m
[31mhigher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. ENALAPRIL MALEATE: adverse_reactions: If angioedema of the face, extremities, lips, tongue, glottis[0m
[31mand/or larynx occurs, treatment with enalapril maleate should be discontinued and appropriate therapy instituted immediately [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m. Hypotension In the hypertensive [0m
[31mpatients, hypotension occurred in [0m[1;31m0.9[0m[31m percent and syncope occurred in [0m[1;31m0.5[0m[31m percent of patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for [0m
[31mdiscontinuation of therapy in [0m[1;31m0.1[0m[31m percent of hypertensive patients. In heart failure patients, hypotension occurred in [0m[1;31m6.7[0m[31m percent and syncope occurred in [0m[1;31m2.2[0m[31m percent of patients. Hypotension or [0m
[31msyncope was a cause for discontinuation of therapy in [0m[1;31m1.9[0m[31m percent of patients with heart failure [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m. Cough See PRECAUTIONS, Cough . ENALAPRIL MALEATE: adverse_reactions: [0m
[31mPediatric Patients The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients. Clinical Laboratory Test Findings Serum Electrolytes Hyperkalemia [0m[1;31m([0m[31msee [0m
[31mPRECAUTIONS, Hyperkalemia [0m[1;31m)[0m[31m, hyponatremia. Creatinine, Blood Urea Nitrogen In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of[0m
[31mtherapy, were observed in about [0m[1;31m0.2[0m[31m percent of patients with essential hypertension treated with enalapril maleate alone. Increases are more likely to occur in patients receiving concomitant diuretics[0m
[31mor in patients with renal artery stenosis [0m[1;31m([0m[31msee PRECAUTIONS, Impaired Renal Function [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: precautions: PRECAUTIONS General Aortic Stenosis/Hypertrophic Cardiomyopathy As with all vasodilators, enalapril should be given with caution to patients with obstruction [0m
[31min the outflow tract of the left ventricle. Impaired Renal Function As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible[0m
[31mindividuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors,[0m
[31mincluding enalapril maleate, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: [0m
[31mprecautions: In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in [0m[1;31m20[0m[31m percent of [0m
[31mpatients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of [0m
[31mtherapy. Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient,[0m
[31mespecially when enalapril maleate has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of [0m
[31mthe diuretic and/or enalapril maleate may be required. Evaluation of patients with hypertension or heart failure should always include assessment of renal function [0m[1;31m([0m[31m see DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. [0m
[31mHyperkalemia Elevated serum potassium [0m[1;31m([0m[31mgreater than [0m[1;31m5[0m[31m. ENALAPRIL MALEATE: precautions: [0m[1;31m7[0m[31m mEq/L[0m[1;31m)[0m[31m was observed in approximately [0m[1;31m1[0m[31m percent of hypertensive patients in clinical trials. In most cases these[0m
[31mwere isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in [0m[1;31m0.28[0m[31m percent of hypertensive patients. In clinical trials in heart failure, [0m
[31mhyperkalemia was observed in [0m[1;31m3.8[0m[31m percent of patients but was not a cause for discontinuation. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the [0m
[31mconcomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with enalapril maleate [0m[1;31m([0m[31msee Drug [0m
[31mInteractions [0m[1;31m)[0m[31m. Cough Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after [0m
[31mdiscontinuation of therapy. ENALAPRIL MALEATE: precautions: ACE inhibitor-induced cough should be considered in the differential diagnosis of cough. Surgery/Anesthesia In patients undergoing major [0m
[31msurgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be [0m
[31mdue to this mechanism, it can be corrected by volume expansion. Information for Patients Angioedema Angioedema, including laryngeal edema, may occur at any time during treatment with [0m
[31mangiotensin-converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema [0m[1;31m([0m[31mswelling of face, extremities, [0m
[31meyes, lips, tongue, difficulty in swallowing or breathing[0m[1;31m)[0m[31m and to take no more drug until they have consulted with the prescribing physician. Hypotension Patients should be cautioned to report [0m
[31mlightheadedness, especially during the first few days of therapy.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Enalapril Maleate can be associated with changes in renal function, which may lead to an increased risk of renal failure in susceptible individuals. In patients with severe heart failure whose[0m
[32mrenal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors, including Enalapril Maleate, may be associated with [0m
[32moliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Increases in blood urea nitrogen and serum creatinine were observed in [0m[1;32m20[0m[32m percent of hypertensive patients with [0m
[32munilateral or bilateral renal artery stenosis, although these increases were almost always reversible upon discontinuation of Enalapril and/or diuretic therapy. In patients with hypertension or heart [0m
[32mfailure with no apparent pre-existing renal vascular disease, increases in blood urea and serum creatinine were usually minor and transient, especially when Enalapril Maleate was given concomitantly [0m
[32mwith a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Therefore, renal function should be monitored during the first few weeks of therapy, and dosage reduction [0m
[32mand/or discontinuation of the diuretic and/or Enalapril Maleate may be required.[0m

[32mSOURCE: ENALAPRIL MALEATE label[0m
[32mEXTRACT_START_END: Impaired Renal Function As a consequence [0m[32m...[0m[32m discontinuation of therapy.[0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Enalapril Maleate can be associated with changes in renal [0m
[34mfunction, which may lead to an increased risk of renal failure in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the [0m
[34mrenin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors, including Enalapril Maleate, may be associated with oliguria and/or progressive azotemia and rarely with [0m
[34macute renal failure and/or death. Increases in blood urea nitrogen and serum creatinine were observed in [0m[1;34m20[0m[34m percent of hypertensive patients with unilateral or bilateral renal artery stenosis, [0m
[34malthough these increases were almost always reversible upon discontinuation of Enalapril and/or diuretic therapy. In patients with hypertension or heart failure with no apparent pre-existing renal [0m
[34mvascular disease, increases in blood urea and serum creatinine were usually minor and transient, especially when Enalapril Maleate was given concomitantly with a diuretic. This is more likely to occur[0m
[34min patients with pre-existing renal impairment. Therefore, renal function should be monitored during the first few weeks of therapy, and dosage reduction and/or discontinuation of the diuretic and/or [0m
[34mEnalapril Maleate may be required.[0m

[34mSOURCE: ENALAPRIL MALEATE label[0m
[34mEXTRACT_START_END: Impaired Renal Function As a consequence [0m[34m...[0m[34m discontinuation of therapy.[0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ENALAPRIL MALEATE increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Enalapril Maleate can be associated with changes in renal function, which may lead to an increased risk of renal failure in susceptible individuals, particularly in [0m
[32mpatients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system. Treatment with Enalapril Maleate in these patients may be associated [0m
[32mwith oliguria, progressive azotemia, and rarely with acute renal failure and/or death. Increases in blood urea nitrogen and serum creatinine were observed in 20 percent of hypertensive patients with [0m
[32mrenal artery stenosis, although these increases were reversible upon discontinuation of the drug. In patients with hypertension or heart failure without apparent pre-existing renal vascular disease, [0m
[32mincreases in blood urea and serum creatinine were usually minor and transient, especially when Enalapril Maleate was given with a diuretic. The risk is higher in patients with pre-existing renal [0m
[32mimpairment, and renal function should be monitored during the first few weeks of therapy."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ENALAPRIL MALEATE can increase the risk of renal failure, particularly in susceptible individuals such as those with severe heart failure or pre-existing renal impairment. Monitoring of[0m
[32mrenal function is recommended during the first few weeks of therapy."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ENALAPRIL MALEATE increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ENALAPRIL MALEATE increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Enalapril Maleate can be associated with changes in renal function, which may lead to an increased risk of renal failure in susceptible individuals, particularly in [0m
[34mpatients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system. Treatment with Enalapril Maleate in these patients may be associated [0m
[34mwith oliguria, progressive azotemia, and rarely with acute renal failure and/or death. Increases in blood urea nitrogen and serum creatinine were observed in 20 percent of hypertensive patients with [0m
[34mrenal artery stenosis, although these increases were reversible upon discontinuation of the drug. In patients with hypertension or heart failure without apparent pre-existing renal vascular disease, [0m
[34mincreases in blood urea and serum creatinine were usually minor and transient, especially when Enalapril Maleate was given with a diuretic. The risk is higher in patients with pre-existing renal [0m
[34mimpairment, and renal function should be monitored during the first few weeks of therapy."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ENALAPRIL MALEATE can increase the risk of renal failure, particularly in susceptible individuals such as those with severe heart failure or pre-existing renal impairment. Monitoring of[0m
[34mrenal function is recommended during the first few weeks of therapy."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ENALAPRIL MALEATE increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ENALAPRIL MALEATE increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that Enalapril Maleate can be associated with changes in renal function, which may lead to an increased risk of renal failure in susceptible individuals, particularly in [0m
[31mpatients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system. Treatment with Enalapril Maleate in these patients may be associated [0m
[31mwith oliguria, progressive azotemia, and rarely with acute renal failure and/or death. Increases in blood urea nitrogen and serum creatinine were observed in [0m[1;31m20[0m[31m percent of hypertensive patients with [0m
[31mrenal artery stenosis, although these increases were reversible upon discontinuation of the drug. In patients with hypertension or heart failure without apparent pre-existing renal vascular disease, [0m
[31mincreases in blood urea and serum creatinine were usually minor and transient, especially when Enalapril Maleate was given with a diuretic. The risk is higher in patients with pre-existing renal [0m
[31mimpairment, and renal function should be monitored during the first few weeks of therapy.[0m
[31m        -----[0m
[31m        Final answer: ENALAPRIL MALEATE can increase the risk of renal failure, particularly in susceptible individuals such as those with severe heart failure or pre-existing renal impairment. [0m
[31mMonitoring of renal function is recommended during the first few weeks of therapy.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mENALAPRIL MALEATE can increase the risk of renal failure, particularly in susceptible individuals such as those with severe heart failure or pre-existing renal impairment. Monitoring of renal function[0m
[32mis recommended during the first few weeks of therapy. This information is based on the response from FDAHandler, which referenced the ENALAPRIL MALEATE label indicating that changes in renal function [0m
[32massociated with the drug may lead to an increased risk of renal failure in certain patients.[0m
